Stock Forecast

  Orphazyme A/S ( ORPH) Stock. Should you Buy or Sell?    $ 0.87

0.00 (0.00 %)

Orphazyme A/S Analysis

Updated on 10-09-2022
Symbol ORPH
Price $0.87
Beta 0.802
Volume Avg. $1.38 M
Market Cap $37.27 M
52 Week Range $0.5101 - $77.77

Orphazyme A/S opened the day at $0.87 which is 0.00 % on yesterday's close. Orphazyme A/S has a 52 week high of $77.77 and 52 week low of $0.5101, which is a difference of $77.2599. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $37.27 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Orphazyme A/S for $37.27 M, it would take 15 years to get your money back. Orphazyme A/S are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Orphazyme A/S Stock Forecast - Is Orphazyme A/S a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -0.227
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Orphazyme A/S

Price Book Value Ratio 0.660 Price To Book Ratio 0.660
Price To Sales Ratio 0.000 Price Earnings Ratio -0.227

How liquid is Orphazyme A/S

Current Ratio 1.805
Quick Ratio 1.805


Debt Ratio 0.610 Debt Equity Ratio 1.567
Long Term Debt To Capitalization 0.119 Total Debt To Capitalization 0.260

Latest news about Orphazyme A/S

Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs

Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to.

Date : 22/03/2022

Dear ORPH Stock Fans, Mark Your Calendars for March 31

After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace.

Date : 22/03/2022

Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is.

Date : 11/03/2022

EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application

Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The application covers arimoclomol for Niemann-Pick disease type C (NPC), a rare genetic.

Date : 24/02/2022

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

Date : 14/02/2022

About Orphazyme A/S

CEO : Ms. Kim Stratton
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Select

Description :

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

My Newsletter

Sign Up For Updates & Newsletters